[HTML][HTML] Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches
The standard of care for patients with stage III non-small-cell lung cancer (NSCLC) is
concurrent chemoradiotherapy (CCRT) followed by 1 year of adjuvant durvalumab. Despite …
concurrent chemoradiotherapy (CCRT) followed by 1 year of adjuvant durvalumab. Despite …
Application of radiomics-based multiomics combinations in the tumor microenvironment and cancer prognosis
W Kang, X Qiu, Y Luo, J Luo, Y Liu, J Xi, X Li… - Journal of Translational …, 2023 - Springer
The advent of immunotherapy, a groundbreaking advancement in cancer treatment, has
given rise to the prominence of the tumor microenvironment (TME) as a critical area of …
given rise to the prominence of the tumor microenvironment (TME) as a critical area of …
The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing
C Wang, Q Yu, T Song, Z Wang, L Song… - … and Targeted Therapy, 2022 - nature.com
A thorough interrogation of the immune landscape is crucial for immunotherapy strategy
selection and prediction of clinical responses in non-small-cell lung cancer (NSCLC) …
selection and prediction of clinical responses in non-small-cell lung cancer (NSCLC) …
The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer
Improved identification of anti-tumor T cells is needed to advance cancer immunotherapies.
CD39 expression is a promising surrogate of tumor-reactive CD8+ T cells. Here, we …
CD39 expression is a promising surrogate of tumor-reactive CD8+ T cells. Here, we …
[PDF][PDF] Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti–PD-1 resistance in non–small cell lung cancer
JM Konen, BL Rodriguez, H Wu… - Journal of Clinical …, 2023 - Am Soc Clin Investig
Non–small cell lung cancers that harbor concurrent KRAS and TP53 (KP) mutations are
immunologically warm tumors with partial responsiveness to anti–PD-(L) 1 blockade; …
immunologically warm tumors with partial responsiveness to anti–PD-(L) 1 blockade; …
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
Although concurrent chemoradiation (CRT) and durvalumab consolidation has become a
standard treatment for stage III non-small cell lung cancer (NSCLC), clinicopathologic and …
standard treatment for stage III non-small cell lung cancer (NSCLC), clinicopathologic and …
[HTML][HTML] The combination of eddy thermal effect of biodegradable magnesium with immune checkpoint blockade shows enhanced efficacy against osteosarcoma
Osteosarcoma (OS) patients have a poor prognosis due to its high degree of heterogeneity
and high rate of metastasis. Magnetic hyperthermia therapy (MHT) combined with …
and high rate of metastasis. Magnetic hyperthermia therapy (MHT) combined with …
Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives
Y Yang, H Liu, Y Chen, N Xiao, Z Zheng, H Liu… - Cell Death & …, 2023 - nature.com
Non-small cell lung cancer (NSCLC) is one of the most threatening malignancies to human
health and life. In most cases, patients with NSCLC are already at an advanced stage when …
health and life. In most cases, patients with NSCLC are already at an advanced stage when …
Toll-like receptor 4 agonist injection with concurrent radiotherapy in patients with metastatic soft tissue sarcoma: a phase 1 nonrandomized controlled trial
Importance Metastatic soft tissue sarcomas (STSs) have limited systemic therapy options,
and immunomodulation has not yet meaningfully improved outcomes. Intratumoral (IT) …
and immunomodulation has not yet meaningfully improved outcomes. Intratumoral (IT) …
Computerized tumor-infiltrating lymphocytes density score predicts survival of patients with resectable lung adenocarcinoma
A high abundance of tumor-infiltrating lymphocytes (TILs) has a positive impact on the
prognosis of patients with lung adenocarcinoma (LUAD). We aimed to develop and validate …
prognosis of patients with lung adenocarcinoma (LUAD). We aimed to develop and validate …